Damora Therapeutics, Inc.

Damora Therapeutics, Inc. is a preclinical stage biopharmaceutical company focused on developing therapies for hematologic disorders, specifically myeloproliferative neoplasms (MPNs) such as essential thrombocythemia (ET) and myelofibrosis (MF) ¹. The company's core business model revolves around the discovery and development of targeted mutation-directed candidates to address the full spectrum of MPN disease, with revenue generation expected only upon successful regulatory approval and commercialization of its product candidates ². The company has a limited operating history and has incurred significant operating losses since its inception in 2011 ³.

The company's lead product candidate, DMR-001, is a monoclonal antibody designed to target mutant forms of calreticulin (mutCALR), which are responsible for approximately 25% of ET cases and 35% of MF cases ⁴. DMR-001 aims to selectively target mutCALR-expressing cells, avoiding adverse effects of non-specific cytoreductive drugs, and has been engineered for increased affinity, potency, and a prolonged half-life compared to other antibodies in development ⁵. Preclinical studies demonstrated DMR-001's approximately ten-fold higher potency on Type 2 mutCALR than a reference antibody with the same mechanism of action as INCA033989, and a five-fold longer half-life in non-human primates compared to a reference mutCALR antibody lacking these modifications ⁶. The company believes DMR-001 has the potential to be a best-in-class therapy for ET and MF, with an estimated addressable market of at least $5 billion in the United States for mutCALR-driven ET and MF ⁷.

In addition to DMR-001, Damora Therapeutics is developing two other anti-mutCALR-based therapies: DMR-002, with an undisclosed mechanism of action, and DMR-003, a bispecific CD3 x anti-mutCALR T cell engager ⁸. The company intends to ultimately address the full spectrum of mutCALR MPN patients with these candidates ⁹. Following a recent portfolio review, the company has deprioritized the continued development of legacy assets, including GB3226 (a small molecule inhibitor for acute myeloid leukemia), GB1211 (a galectin-3 inhibitor candidate), and GB2064 (a LOXL-2 inhibitor candidate), and plans to explore corporate partnerships for their advancement and commercialization ¹⁰.

For the fiscal year ended December 31, 2025, Damora Therapeutics reported a net loss of $209.8 million, a significant increase from the $21.4 million net loss in the prior year ¹¹. Total operating expenses for 2025 were $210.872 million, up from $22.260 million in 2024 ¹². Research and development expenses increased to $26.877 million in 2025 from $6.398 million in 2024, primarily driven by $9.4 million in costs related to the Paramora Warrant, $5.3 million in increased preclinical studies and clinical trial-related expenses, $5.7 million in increased chemistry, manufacturing and control (CMC) activities, and $2.2 million in increased consulting and other R&D costs, partially offset by a $2.1 million decrease in personnel costs ¹³. Acquired in-process research and development costs surged to $174.310 million in 2025 from $4.395 million in 2024, mainly due to the Asset Acquisition ¹⁴. General and administrative expenses decreased by $0.8 million to $9.685 million in 2025 from $10.499 million in 2024, primarily due to a $1.6 million decrease in stock-based compensation costs, partially offset by a $0.5 million increase in personnel costs and a $0.3 million increase in other general and administrative costs ¹⁵. The company had no restructuring costs in 2025, compared to $968 thousand in 2024 ¹⁶. Other income, net, increased to $1.1 million in 2025 from $0.9 million in 2024, primarily due to increased interest income, net, offset by increased foreign exchange loss, net ¹⁷. As of December 31, 2025, the company had an accumulated deficit of $487.4 million and cash and cash equivalents of $257.6 million ¹⁸.

A significant operational development was the Asset Acquisition of Pre-Acquisition Damora on November 10, 2025, a stock-for-stock transaction involving the exchange of equity interests for 265,309 shares of common stock, 16,366 shares of Series B non-voting convertible preferred stock, and 4,241 shares of Series C non-voting convertible preferred stock, plus the assumption of 434,508 stock options ¹⁹. Concurrently, the company completed a $285 million private investment in public equity (PIPE) with existing and new investors, issuing 39,641 shares of Series C Preferred Stock at $7,186.90 per share ²⁰. The net proceeds from the PIPE were $266.8 million ²¹. The company also assumed the rights and obligations under the Paragon Option Agreement, under which it exercised its option to license exclusive worldwide development and commercialization rights to DMR-001 ²². In January 2026, the company paid $1.25 million for each of the DMR-001, DMR-002, and DMR-003 research initiation fees, and recognized $1.5 million in R&D expense for a DMR-001 development candidate milestone in December 2025, which was paid in January 2026 ²³. On February 9, 2026, stockholders approved the conversion of Series B and C Preferred Stock and an increase in authorized common stock from 300,000,000 to 500,000,000 shares, leading to the automatic conversion of 42,005 shares of Series C Preferred Stock into 42,005,000 shares of common stock ²⁴. On February 10, 2026, the company filed a shelf registration statement and entered into an ATM offering program for up to $150.0 million, with no sales made to date ²⁵. Also on February 10, 2026, the company completed an underwritten public offering of 14,473,685 shares of common stock at $19.00 per share, generating approximately $297.3 million in net proceeds ²⁶. The company also changed its name from "Galecto, Inc." to "Damora Therapeutics, Inc." effective March 10, 2026 ²⁷.

Damora Therapeutics anticipates filing an Investigational New Drug Application (IND) or Clinical Trial Application (CTA) for DMR-001 in mid-2026, with the initiation of a Phase 1 trial in ET and MF patients with a subcutaneous formulation thereafter, subject to regulatory approval ²⁸. Two proof-of-concept readouts for DMR-001 are expected beginning mid-2027 ²⁹. The company also plans to file an IND or CTA for DMR-002 in the second half of 2026 and for DMR-003 in 2027 ³⁰. Management believes its existing cash and cash equivalents of $257.6 million as of December 31, 2025, will be sufficient to fund operations into Phase 3 development of DMR-001 ³¹.

The primary growth area for Damora Therapeutics is its mutCALR portfolio, which includes DMR-001, DMR-002, and DMR-003, aimed at addressing the full spectrum of mutCALR-driven myeloproliferative neoplasms (MPNs) ³². DMR-001 is positioned as a potential best-in-class anti-mutCALR therapy due to its preclinical demonstration of approximately ten-fold higher potency on Type 2 mutCALR and a five-fold longer half-life in non-human primates compared to a reference antibody ³³. This enhanced profile is expected to enable convenient, infrequent, and low-volume subcutaneous dosing, potentially matching or exceeding the efficacy of intravenously administered INCA033989 ³⁴. The addressable market in the United States for mutCALR-driven ET and MF is estimated to be at least $5 billion ³⁵.

The company's strategy includes investing early in preparation for late-stage development of DMR-001 to minimize unnecessary delays and to be in a position to execute additional clinical trials in response to both internal results and competitor developments ³⁶. Furthermore, DMR-002 and DMR-003 are being developed as mutCALR-targeted therapies designed to be even more potent than DMR-001, with the goal of addressing the full spectrum of mutCALR-driven MPNs ³⁷. The company plans to disclose specifics about DMR-002 and DMR-003 as they advance into formal clinical development ³⁸.

Operationally, the company expects its research and development expenses to increase substantially as it continues to invest in R&D activities, including manufacturing, for its current and future product candidates, particularly as they advance into and through clinical development ³⁹. General and administrative expenses are also expected to increase due to anticipated headcount growth and the establishment of office space, as well as increased costs associated with operating as a public company, including accounting, audit, legal, regulatory, and intellectual property-related expenses ⁴⁰. The company has historically received a tax credit in Denmark of up to $0.8 million per year for R&D losses up to approximately $3.9 million per year, which is reported as a reduction to R&D expense ⁴¹.

The company does not own or operate any manufacturing facilities and plans to continue outsourcing all preclinical and clinical drug supply development, manufacturing, storage, distribution, and testing to third-party manufacturers ⁴². This strategy is intended to direct financial resources more efficiently to research, development, and commercialization ⁴³. The company recently entered into an agreement with a second supplier for its product candidates, diversifying from a single source ⁴⁴. The company also plans to build focused company infrastructure and foster a positive corporate culture, incorporating commitments to science-driven drug development and rapidly addressing patient needs in hematologic disorders ⁴⁵.

The company will require substantial additional capital to finance its operations beyond Phase 3 development of DMR-001 ⁴⁶. It expects to seek additional funding through private or public equity or debt financings, loans, or other capital sources, including income from collaborations, partnerships, or grants ⁴⁷. The company's ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and volatility in credit and financial markets ⁴⁸. The company has not declared or paid any cash dividends and intends to retain all available funds and future earnings for business growth ⁴⁹.

The company faces structural headwinds and execution risks, including the lengthy, expensive, and unpredictable nature of regulatory approval processes, and the potential for delays or failures in preclinical studies and clinical trials ⁵⁰. The target patient population for MPNs is considered small and estimates may prove inaccurate, potentially impacting future revenues ⁵¹. The unproven nature of the company's approach to discovery and development, particularly regarding half-life extension technologies and enhanced binding affinity, poses a risk that these efforts may not result in viable product candidates or translate into improved efficacy in humans ⁵². The company is substantially dependent on the success of DMR-001, and its failure would materially harm the business ⁵³. Competition from other biopharmaceutical companies, including those with greater financial resources and more advanced product candidates, is a significant risk ⁵⁴. The company also relies heavily on third parties for preclinical studies, clinical trials, and manufacturing, and their failure to perform could adversely affect development timelines and regulatory approval ⁵⁵. Geopolitical instability, trade restrictions, and changes in foreign regulatory requirements, such as the BIOSECURE Act impacting foreign CMOs like WuXi Biologics (Hong Kong), could increase costs, reduce supply, or restrict the company's ability to work with certain partners ⁵⁶.

Damora Therapeutics faces several material risks, including its limited operating history as a preclinical stage biotechnology company with no commercially approved products, necessitating substantial additional capital to finance future operations, which may not be available on acceptable terms and could force delays or elimination of research programs ⁵⁷. The company is substantially dependent on the success of its lead product candidate, DMR-001, and its anticipated clinical trials may not be successful, particularly if the observed preclinical potency and pharmacokinetic improvements do not translate to humans ⁵⁸. Competition from numerous biopharmaceutical companies, including those with greater resources and more advanced product candidates, poses a significant threat to market penetration, especially given the small and uncertain target patient population for MPNs ⁵⁹. Reliance on third-party collaborations, such as with Paragon, and contract manufacturing organizations (CMOs) introduces risks of delays, non-compliance, or disruptions, including potential impacts from U.S. legislation like the BIOSECURE Act on foreign CMOs ⁶⁰. The regulatory approval processes are lengthy, expensive, and unpredictable, with no guarantee of approval or that any approval will be for broad indications, and the company will be subject to extensive ongoing regulatory obligations and potential penalties for non-compliance ⁶¹. Intellectual property protection is at an early stage and uncertain, exposing the company to potential loss of competitive advantage, challenges to patent validity, and the risk of infringement claims ⁶². Macroeconomic conditions, including inflation, fluctuating interest rates, geopolitical events, and trade policies, could adversely affect the company's operations, financial condition, and ability to raise capital ⁶³.

Management's message emphasizes a strategic pivot towards developing therapies for hematologic disorders, particularly myeloproliferative neoplasms (MPNs), following the Asset Acquisition of Pre-Acquisition Damora in November 2025 ⁶⁴. The company's primary strategic priority is the advancement of its mutCALR portfolio, with a specific focus on its lead product candidate, DMR-001, which is designed to be a best-in-class anti-mutCALR therapy for essential thrombocythemia (ET) and myelofibrosis (MF) ⁶⁵. Management intends to file an Investigational New Drug Application (IND) or Clinical Trial Application (CTA) for DMR-001 in mid-2026 and initiate a Phase 1 trial in ET and MF patients with a subcutaneous formulation thereafter, subject to regulatory approval, with two proof-of-concept readouts expected beginning mid-2027 ⁶⁶. A second strategic priority involves advancing DMR-002 and DMR-003 into clinical development, with IND/CTA filings anticipated in the second half of 2026 and 2027, respectively, to address the full spectrum of mutCALR-driven MPNs ⁶⁷. The third key strategic priority is to build focused company infrastructure and foster a positive corporate culture, incorporating commitments to science-driven drug development and rapidly addressing patient needs ⁶⁸. Management explicitly states that existing cash and cash equivalents of $257.6 million as of December 31, 2025, are believed to be sufficient to fund operations into Phase 3 development of DMR-001 ⁶⁹.